Tag: GlobeNewswire

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.

Late-Breaking Clinical Trial Presentations

Title: Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results from ACACIA-HCM
Presenter: Martin Maron, M.D., Director, Hypertrophic Cardiomyopathy Center, Lahey Hospital & Medical Center; and National Principal Investigator of SEQUOIA-HCM
Date: Monday, October 12, 2026
Session Title: Monday Plenary Session: Late-Breaking Evidence from Novel Therapies to Real-World Outcomes
Session Time: 9:00 – 10:30 AM MST
Presentation Time: 9:26 – 9:33 AM MST
Location: Ballroom BCD, PCC North

Title: Aficamten Improves Comprehensive Measures of Exercise Performance in Non-Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of ACACIA-HCM
Presenter: Gregory Lewis, M.D., Jeffrey and Mary Ellen Jay Chair and Section Head, Heart Failure Medical Director, Cardiopulmonary Exercise Testing (CPET) Laboratory, Professor of Medicine, Harvard Medical School
Date: Monday, October 12, 2026
Session Title: Monday Plenary Session: Late-Breaking Evidence from Novel Therapies to Real-World Outcomes
Session Time: 9:00 – 10:30 AM MST
Presentation Time: 9:34 – 9:41 AM MST
Location: Ballroom BCD, PCC North

Oral Presentations

Title: Association Of Aficamten Treatment With Right Ventricular Function And Pulmonary Coupling In Obstructive Hypertrophic Cardiomyopathy: Results From The SEQUOIA-HCM Trial
Presenter: Yasuhiro Hamatani, M.D., Ph.D., Cardiologist, Brigham and Women’s Hospital, Harvard Medical School
Date: Saturday, October 10, 2026
Session Title: Oral Abstract Session 3A
Session Time: 12:45 – 2:15 PM MST
Presentation Time: 12:57 – 1:07 PM MST
Location: Oral Abstract Stage 1 – Exhibit Hall 5-6, PCC North

Title: Dosing and Safety of Aficamten for Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy in the ACACIA-HCM Trial
Presenter: Ahmad Masri, M.D., M.S., Associate Professor of Medicine, Director of the Hypertrophic Cardiomyopathy Center at Oregon Health & Science University
Date: Sunday, October 11, 2026
Session Title: Rapid Fire Abstract Session 1
Session Time: 10:45 AM – 11:45 AM MST
Presentation Time: 11:38 – 11:45 AM MST
Location: 126 ABC, PCC North

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO^® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union and United Kingdom for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the enrollment, expected results or timing of completion of any of our clinical trials, the clinical meaningfulness, persuasiveness or interpretation of clinical trial results, including for purposes of regulatory approval, labeling, or market acceptance, the results of long-term, secondary or exploratory analyses, including analyses of time to first cardiovascular event, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any jurisdiction by any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten, or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics’ drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics’ drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission including the risk factors included in Cytokinetics’ most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

CYTOKINETICS^® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO^® is a registered trademark of Cytokinetics in the U.S. and the European Union.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) —  InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 – 25.

Kidney Week 2026 Late-Breaking Poster Details

Title: Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models.

Poster Session
Session Title: Late-Breaking Research Posters [LB-PO]
Session Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM

About izicopan
Izicopan is an orally administered, small molecule inhibitor of the C5a receptor (C5aR) that has shown anti-inflammatory therapeutic effects in several pre-clinical disease models and in human studies. InflaRx is planning for development of izicopan in ANCA-associated vasculitis (AAV) and additional renal indications.
In contrast to the marketed C5aR inhibitor, in vitro experiments demonstrated that izicopan does not exhibit time-dependent inhibition of cytochrome P450 3A4 (CYP3A4), which plays an important role in the metabolism of a variety of metabolites and drugs, including glucocorticoids. Izicopan has also demonstrated a favorable reactive metabolite profile in human liver microsomes. Reported results from a first-in-human study demonstrated that izicopan was well tolerated in treated subjects and exhibited no safety signals of concern in single doses ranging from 3 mg to 240 mg or multiple doses ranging from 30 mg once per day to 90 mg twice per day for 14 days. Pharmacokinetic / pharmacodynamic data support the best-in-class potential of izicopan, with a ≥90% blockade of C5a-induced neutrophil activation achieved over the 14-day dosing period. Topline Phase 2a data further support the safety profile of izicopan, with no reported safety signals of concern. In patients with hidradenitis suppurativa, over 4 weeks of therapy, izicopan provided rapid and clinically meaningful reductions in abscesses and nodules and draining tunnels, robust HiSCR responses that continued to deepen four weeks after the treatment period, and substantial reductions in patient-reported pain scores, overall demonstrating the potential for biologic-like efficacy. In chronic spontaneous urticaria, InflaRx observed substantial reductions in the 7-day Urticaria Activity Score (UAS7) broadly across patients and particularly in those with severe disease, as well as improved disease control as measured by the Urticaria Control Test (UCT7).

About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx‘s lead program is izicopan, an orally administered small molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD characteristics as well as therapeutic potential in Phase 1 and Phase 2a clinical studies. The Company is developing izicopan for the treatment of ANCA-associated vasculitis and additional renal diseases. InflaRx also has developed vilobelimab, a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies.

InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.de. Follow InflaRx on LinkedIn. InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are wholly owned subsidiaries of InflaRx N.V. (together, InflaRx).

Contacts:

InflaRx N.V.	MC Services AG
Jan Medina, CFA Vice President, Head of Investor Relations Email: IR@inflarx.de	Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: inflarx@mc-services.eu Europe: +49 89-210 2280 U.S.: +1-339-832-0752

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue,” among others. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading “Risk Factors” and “Cautionary statement regarding forward looking statements” in our periodic filings with the SEC. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 128,250 shares of common stock to nine (9) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price equal to $10.65 per share, the closing price of the Company’s common stock on October 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI^® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn.

Kura Contact

Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

CLEVELAND, Ohio, Oct. 02, 2026 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On September 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to two individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 7,200 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee are scheduled to be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN^® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio, serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN^®, Abeona Assist^®, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

CONTACT: Contacts:

Investor and Media:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor:
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

ROAD TOWN, British Virgin Islands, Oct. 02, 2026 (GLOBE NEWSWIRE) — Aura Minerals Inc. (“Aura” or the “Company”) (NASDAQ: AUGO | B3: AURA33) announced today that it has signed a definitive agreement to acquire a company (“Newco”) that will hold the mining fleet, related equipment leases and dedicated workforce currently operated by a third-party contractor in three of its gold operations in Brazil — Apoena, Almas and Borborema — and to bring fleet operation and maintenance in-house (the “Insourcing”), with the transition targeted for January 2027. At MSG, the Company already operates the mine fleet directly.

The Insourcing is expected to give Aura greater operational control and to generate synergies across its Brazilian business units. The timing is aligned with the Company’s growth in the country where it currently operates four gold mines and plans to expand production capacity in some of its operations. The Insourcing will give Aura direct control over fleet sizing, maintenance strategy and utilization at all three operations, and is expected to improve equipment availability and reliability and lower mining unit costs over time.

The agreed consideration for the acquisition (the “Enterprise Value”) is R$612 million (approximately US$118 million¹), of which up to R$250 million will be paid in cash, with the remainder consisting of the assumption of existing equipment lease financing and the retention of other contingent payments typical for this type of transaction. The transaction structure is designed to align the seller with a smooth transition, with a portion of the consideration subject to performance during the transition period. As part of the transaction, Aura will also absorb the existing workforce dedicated to fleet operation and maintenance at the three operations, ensuring continuity and avoiding disruption to operations after the acquisition is completed.

Based on the Company’s internal estimates, the Insourcing is expected to reduce all-in sustaining costs (AISC) by US$150 to US$200 per ounce of gold sold, on a weighted-average basis across the three operations, beginning in 2027².

The Insourcing will give Aura direct control over fleet sizing, maintenance strategy and utilization at all three operations, and is expected to improve equipment availability and reliability and lower mining unit costs over time. Both the transition and the ongoing management of the Newco will be led by a new dedicated team with experience in managing mine fleet operations.

Closing of the transaction is subject to customary conditions precedent, including antitrust clearance from Brazil’s Administrative Council for Economic Defense (CADE).

Rodrigo Barbosa, CEO and President, commented: “Over the past three years, we have grown from one operation in Brazil to four, including MSG, which we acquired with its own mine fleet already in place. Insourcing the mine operations is a natural next step in that growth strategy and in our ongoing focus on cost reduction. The Insourcing is expected to deliver a robust return on invested capital through an average AISC reduction of US$150 to US$200 per ounce across our three open-pit mines, while giving us greater operational control to pursue further productivity gains and economies of scale.”

About Aura 360° Mining

Aura is focused on mining in complete terms – thinking holistically about how its business impacts and benefits every one of our stakeholders: our company, our shareholders, our employees, and the countries and communities we serve. We call this 360° Mining.

Aura is a company focused on the development and operation of gold and base metal projects in the Americas. The Company’s six operating assets include Minosa gold mine in Honduras; Almas, Apoena, Borborema and MSG gold mines in Brazil; and Aranzazu, a copper, gold, and silver mine in Mexico. Additionally, the Company owns Era Dorada, a gold project in Guatemala; Tolda Fria, a gold project in Colombia; and two projects in Brazil: Matupá, which is under development; and the Carajás copper project in the Carajás region, in the exploration phase.

Forward-Looking Information

This press release contains “forward-looking information” and “forward-looking statements”, as defined in the U.S. Private Securities Litigation Reform Act of 1995 and applicable securities laws (collectively, “forward-looking statements”) which include, but are not limited to, statements with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, including the expected acquisition, satisfaction of the conditions precedent to the acquisition, Insourcing, estimates as to the impacts on the all-in sustaining costs (AISC) of the Insourcing, including the anticipated timing and results thereof.

Known and unknown risks, uncertainties and other factors, many of which are beyond the Company’s ability to predict or control, could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Specific reference is made to the most recent 20-F filed with the U.S. Securities and Exchange Commission for a discussion of some of the factors underlying forward-looking statements, which include, without limitation, the ability of the Company to achieve its short-term and longer-term outlook and the anticipated timing and results thereof, the ability to lower costs and increase production, the ability of the Company to successfully achieve business objectives, copper and gold or certain other commodity price volatility, changes in debt and equity markets, the uncertainties involved in interpreting geological data, increases in costs, environmental compliance and changes in environmental legislation and regulation, interest rate and exchange rate fluctuations, general economic conditions and other risks involved in the mineral exploration and development industry. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect the forward-looking statements.

All forward-looking statements herein are qualified by this cautionary statement. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements whether as a result of new information or future events or otherwise, except as may be required by law. If the Company does update one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those or other forward-looking statements.

______________
¹ Calculated in R$ and converted to US$ at an exchange rate of R$5.18/ US$1.00
² Expected AISC reduction on weighted average basis of the three operations. AISC is a non-IFRS measure and does not have a standardized meaning within IFRS and therefore may not be comparable to similar measures presented by other companies. The Company does not provide a reconciliation of forward-looking AISC to the most directly comparable financial measure calculated and presented in accordance with IFRS because such reconciliations cannot be provided without unreasonable effort and such information is not available given the difficulty of projecting event-driven transactional and other non-core operating items in any future period.

CONTACT: For further information, please visit Aura’s website at www.auraminerals.com or contact: ri@auraminerals.com

OAK BROOK, Ill., Oct. 02, 2026 (GLOBE NEWSWIRE) — Hub Group, Inc. (Nasdaq: HUBG) (“Hub Group” or the “Company”) today announced changes to its Board of Directors (the “Board”) following an action by written consent of its controlling shareholders.

On October 1, 2026, shareholders representing a majority of the combined voting power of the Company’s outstanding common stock, consisting of members of the Yeager family and related trusts, acted by written consent to:

• Appoint Gregory D. Bunch, Thomas P. Fitzgerald, Thaddeus J. Malik and Thomas M. White to the Board;
• Remove Michael Flannery, Peter McNitt and Gary Yablon from the Board without cause; and
• Adopt the Company’s Second Amended and Restated Bylaws.

These actions took effect upon delivery of the written consent to the Company’s Corporate Secretary, in accordance with Delaware law and the Company’s bylaws. Each newly appointed director will serve until the Company’s next annual meeting of shareholders or until his earlier death, termination, resignation or removal. Following the delivery of the written consent, Mary H. Boosalis, Jenell Ross and Martin P. Slark resigned from the Board, effective October 1, 2026.

The Board now consists of seven (7) directors: David P. Yeager (Chairman), Phillip D. Yeager (Vice Chairman), Gregory D. Bunch, Thomas P. Fitzgerald, James C. Kenny, Thaddeus J. Malik and Thomas M. White. The Board intends to appoint a new Lead Independent Director as soon as practicable and will also reconstitute its standing committees.

The Company intends to maintain a majority-independent Board and fully independent Compensation and Nominating and Governance Committees, and will continue to meet Nasdaq and U.S. Securities and Exchange Commission (“SEC”) audit committee independence requirements.

The Board changes do not affect the Company’s management team, strategy or day-to-day operations. David P. Yeager remains Chairman and Chief Executive Officer, and Phillip D. Yeager remains President and Vice Chairman. The leadership changes announced on September 14, 2026 are also unaffected.

“We believe that the newly appointed directors will bring valuable perspectives and relevant expertise to the Board’s oversight of the Company’s management, business and ongoing initiatives,” said David P. Yeager. “They intend to work constructively and collaboratively with the continuing directors to advance the best interests of Hub Group and all of its stakeholders. We will remain focused on our long-term strategy to drive growth, profitability and operating cash flows, as we work to deliver for our shareholders, customers and team members.”

The Company’s finance and accounting team continues to work expeditiously to complete the restatement process and file the Company’s delayed periodic reports. Hub Group continues to expect to complete this process in the fourth quarter of 2026. As previously announced, on September 16, 2026, the Company received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), which notified the Company that it had initiated a process to delist the Company’s Class A common stock. The Staff Determination was issued because the Company has not filed its Annual Report on Form 10-K for the year ended December 31, 2025 and its Quarterly Reports on Form 10-Q for the periods ended March 31, 2026 and June 30, 2026, and therefore is not in compliance with Nasdaq Listing Rule 5250(c)(1). Receipt of the Staff Determination did not immediately result in the suspension of trading or delisting of the Company’s Class A common stock.

The Company has appealed the Staff Determination by requesting a hearing before the Nasdaq Hearings Panel. The Company requested, and has been granted, a stay of the delisting action pending the outcome of the hearing currently scheduled for October 27, 2026.

Additional information is included in the Company’s Current Report on Form 8-K filed with the SEC on October 2, 2026.

Biographies of the Newly Appointed Directors

Gregory D. Bunch
Mr. Bunch, age 67, has served as an Adjunct Professor of Entrepreneurship at the University of Chicago Booth School of Business for nearly twenty (20) years, teaching entrepreneurship, growth strategy, competitive strategy, innovation, marketing and mergers and acquisitions in both the MBA program and Executive Education. He is also the owner of Gregory Bunch Consulting, a management consulting firm. Mr. Bunch was the founder and Chief Executive Officer of Masterplan International Corporation, a strategy consultancy, from 1998 to 2018, and co-founded Oration Health, a healthcare software-as-a-service business. He was also a partner in Brandtrust, a brand strategy consultancy. Over the course of his career, he has advised hundreds of startups and dozens of publicly and privately held corporations, and has served as an Independent Trustee of Elkhorn Investments from its founding until its sale to Innovator, as well as on advisory boards for companies in the financial services, consulting, retail, franchising and marketing industries. Mr. Bunch has lectured nationally and internationally on topics related to strategy, creating customers and innovation. He earned a bachelor’s degree in philosophy from Wheaton College and an MDiv from Harvard University.

Thomas P. Fitzgerald
Mr. Fitzgerald, age 72, was a partner at Winston Taylor LLP (formerly known as Winston & Strawn LLP), an international law firm. From 2006 to June 2024, Mr. Fitzgerald served as Chairman and Managing Partner of the firm’s Executive Committee. Under his leadership, the firm opened ten (10) offices on three continents and significantly expanded its practice and sector offerings, including in private equity, finance, funds, intellectual property, complex commercial litigation and real estate. Over the course of his tenure, Mr. Fitzgerald also advanced the firm’s client initiatives in the financial services, technology, energy, and life sciences sectors. Mr. Fitzgerald holds a B.A. from the University of Notre Dame and a J.D., with honors, from the Notre Dame Law School.

Thaddeus J. Malik
Mr. Malik, age 59, has served as President and Principal of S2T Solutions LLC, a transactional advisory services company, since 2022. Previously, he was a partner at Paul Hastings LLP, an international law firm, from 2010 to 2022, a partner at Jenner & Block LLP from 2002 to 2010, and Vice President and General Counsel of Lante Corporation, a formerly publicly traded technology consulting company, from 2000 to 2002. Mr. Malik has more than thirty (30) years of experience as a corporate and securities advisor to boards and committees of public companies and as a mergers and acquisitions attorney. He has served as an independent director of CenterPoint Energy, Inc. (NYSE: CNP) since September 2023, where he currently serves on the Corporate Governance and Nominating Committee and the Human Capital and Compensation Committee and previously served on the Audit and Compliance Committee and the Safety and Operations Committee. He also served as an independent director of Health Care Service Corporation, the parent of Blue Cross and Blue Shield of Illinois, Texas, Montana, Oklahoma and New Mexico, from 2019 to 2025. Mr. Malik holds a B.A. from Northwestern University and a J.D. from Harvard Law School, and has earned director certifications from the National Association of Corporate Directors and Harvard Business School, as well as the CERT Certificate in Cybersecurity Oversight from the Carnegie Mellon University Software Engineering Institute.

Thomas M. White
Mr. White, age 69, is a global business leader and experienced board member with over forty five (45) years of experience in financial and operational management. Mr. White previously served as the Company’s Chief Financial Officer and Senior Vice President from 2002 to 2007. From 2007 to 2014, he served as an Operating Partner of Apollo Global Management, Inc. (NYSE: APO), a leading global alternative investment manager, where he assumed senior leadership positions in key portfolio companies, including as Interim Chief Operating Officer and Interim Chief Financial Officer of CEVA Logistics and Interim Chief Financial Officer of Constellium N.V. (NYSE: CSTM). Previously, Mr. White served for twenty three (23) years at Arthur Andersen LLP, where he held leadership positions including Global Managing Partner of Business Process Outsourcing and Office Managing Partner. Mr. White served as Chairman of the Board of Directors of Sterling Infrastructure, Inc. (Nasdaq: STRL) from 2019 to 2024, and has served as a member of the board of directors of JPW Industries, a private industrial machinery company. Mr. White holds a B.B.A. in Accountancy from Western Michigan University and an M.S. in Business Administration from Purdue University.

Certain Forward-Looking Statements
Statements in this press release that are not historical facts are forward-looking statements, provided pursuant to the safe harbor established under the Private Securities Litigation Reform Act of 1995, including statements regarding the outcome of the Company’s appeal to the Nasdaq Hearings Panel, the Company’s plans to regain full compliance with Nasdaq’s continued listing requirements, and any other statements regarding Hub Group’s future expectations, beliefs, plans, objectives, financial conditions, assumptions or future events or performance that are not historical facts.

These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and other factors that might cause the actual performance of Hub Group to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s ability to complete the previously-announced restatement of its financial statements and regain compliance with Nasdaq’s listing rules; unanticipated delays that cause the Company’s delinquent periodic reports to be filed later than currently expected; the risk that its plan to regain compliance with Nasdaq’s continued listing requirements will not be accepted by the Nasdaq Hearings Panel or, if accepted, will not allow for sufficient time for the Company to regain compliance; the impact that the restatement process and further delays in the financial close process or the related audit may have on Hub Group’s business, financial condition and results of operations; and other risks discussed under the “Risk Factors” section in Hub Group’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings.

These forward-looking statements speak only as of the date hereof and Hub Group assumes no obligation to update any such forward-looking statements.

About Hub Group
Hub Group offers comprehensive transportation and logistics management solutions. Keeping our customers’ needs in focus, Hub Group designs, continually optimizes, and applies industry-leading technology to our customers’ supply chains for better service, greater efficiency, and total visibility. As an award-winning, publicly traded company (Nasdaq: HUBG), our approximately 6,000 employees and drivers across the globe are always in pursuit of “The Way Ahead” – a commitment to service, integrity and innovation. For more information, visit hubgroup.com.

CONTACT:

Garrett Holland, InvestorRelations@hubgroup.com

OR

Longacre Square Partners
HUBG@longacresquare.com

MONTREAL, Oct. 02, 2026 (GLOBE NEWSWIRE) —

OPEN TO:                 Analysts, investors and all interested parties

DATE:                        Friday, October 9, 2026

TIME:                         8:30 AM Eastern Time

RAPIDCONNET:       To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/4A3Xmi9

CALL:                        1-416-945-7677 (For all International participants)
                                   1-888-699-1199 (For all other North American participants)

Participants can access a webcast of the conference by navigating to: https://app.webinar.net/AWzv1Lq7Ma0

THE THIRD QUARTER RESULTS WILL BE PUBLISHED OCTOBER 9, 2026, BEFORE THE CONFERENCE CALL.

Please dial in 15 minutes before the conference begins.

If you are unable to call in at this time, you may access a recording of the meeting by calling the following:

North America Toll Free: 1-888-660-6345
International participants: 1-289-819-1450
Enter access code 28098# on your phone.

MEDIA WISHING TO QUOTE AN ANALYST SHOULD CONTACT THE ANALYST PERSONALLY FOR PERMISSION.

For further information, please contact Eric Lefebvre at 514-336-8885.

Common stock expected to begin trading on TXSE on October 19, 2026, under existing ticker symbol “CECO”

ADDISON, Texas, Oct. 02, 2026 (GLOBE NEWSWIRE) — CECO Environmental Corp. (Nasdaq: CECO) (“CECO”), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today announced that its Board of Directors has approved the voluntary transfer of the primary listing of the Company’s common stock, par value $0.01 per share, from the Nasdaq Global Select Market (“Nasdaq”) to the Texas Stock Exchange (“TXSE”).

Subject to customary conditions, CECO expects its common stock to cease trading on Nasdaq at the market close on Friday, October 16, 2026, and begin trading on TXSE at the market open on Monday, October 19, 2026. CECO’s common stock will continue trading under the ticker symbol CECO and retain its existing CUSIP. The transfer is not expected to affect the Company’s operations, financial condition, reporting obligations, or stockholders’ rights, and stockholders need not take any action. The transfer reflects CECO’s strategic alignment with Texas as a growing center for business, innovation, and capital markets.

Todd Gleason, CECO’s Chairman and Chief Executive Officer, commented: “CECO has been on a multi-year transformation journey diversifying our portfolio while delivering high-performance financial results and shareholder returns. By becoming the first multi-industrial company to transfer its primary listing to the Texas Stock Exchange, we are aligning with a well-capitalized, leading technology platform that introduces a new era of competitive growth in U.S. capital markets. We appreciate Nasdaq’s partnership and support throughout CECO’s growth as a public company.”

“This move builds upon our strong presence in Texas, which includes our global headquarters in Addison and a large employee base in the state. Texas is currently the most dynamic economic market in the United States, attracting an influx of investment and business growth. Strengthening our alignment with this dynamic growth environment advances CECO’s position as a leader in industrial markets,” added Gleason.

“A high-growth, global leader like CECO can list anywhere — and today it chose Texas,” said TXSE Chairman and CEO James H. Lee. “For six decades, CECO has provided the innovation that has kept American industry clean, safe, and running. Manufacturers make America, and we are proud CECO will become the first industrial company to place its primary listing on the Texas Stock Exchange.”

About CECO

CECO Environmental is a leading environmentally focused, diversified industrial company, serving a broad landscape of industrial air, industrial water, and energy transition markets globally through its key business segments: Engineered Systems and Industrial Process Solutions. Providing innovative technology and application expertise, CECO helps companies grow their business with safe, clean, and more efficient solutions that help protect people, the environment and industrial equipment. In regions around the world, CECO works to improve air quality, optimize the energy value chain, and provide custom solutions for applications in power generation, petrochemical processing, refining, midstream gas transport and treatment, electric vehicle and battery production, metals and mineral processing, polysilicon production, battery recycling, beverage can production, and produced and oily water/wastewater treatment, along with a wide range of other industrial applications. CECO’s common stock trades under the ticker symbol “CECO.” Incorporated in 1966, CECO’s global headquarters is in Addison, Texas. For more information, please visit www.cecoenviro.com.

Forward-Looking Statements:

Any statements contained in this press release, other than statements of historical fact, including statements about management’s beliefs and expectations, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, both as amended, and are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995, and should be evaluated as such. These statements are made on the basis of management’s views and assumptions regarding future events and business performance. We use words such as “believe,” “expect,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “will,” “plan,” “should” and similar expressions to identify forward-looking statements.

Forward-looking statements in this Press Release include, but are not limited to, statements regarding the planned transfer of the primary listing of our common stock from Nasdaq to the Texas Stock Exchange and the anticipated timing and effects of such transfer.

Forward-looking statements involve risks and uncertainties that may cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Potential risks and uncertainties, among others, that could cause actual results to differ materially are discussed under “Part I – Item 1A. Risk Factors” of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and under “Part II – Item 1A. Risk Factors” of the Company’s Quarterly Reports on Form 10-Q and include, but are not limited to, risks related to delays in the timing for implementing the listing transfer, potential market disruptions with respect to the trading of the common stock, potential impacts on the Company’s business or operations as it implements the listing transfer, and risks that applicable approvals, conditions, or regulatory requirements relating to the listing transfer may not be satisfied in the anticipated timeframe or at all.

Many of these risks are beyond management’s ability to control or predict. Should one or more of these risks or uncertainties materialize, or should any related assumptions prove incorrect, actual results may differ materially from those currently anticipated. Investors are cautioned not to place undue reliance on such forward-looking statements as they speak only to our views as of the date the statement is made. Except as required under the federal securities laws or the rules and regulations of the Securities and Exchange Commission, we undertake no obligation to update or review any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

CECO Investor Relations Contacts:
Marcio Pinto
Vice President – Integration & Investor Relations
Investor.Relations@OneCECO.com

Steven Hooser and Jean Marie Young
Three Part Advisors, LLC
214-872-2710
Investor.Relations@OneCECO.com

LIVONIA, Mich., Oct. 02, 2026 (GLOBE NEWSWIRE) — Alta Equipment Group Inc. (NYSE: ALTG) (“Alta” or “the Company”), a leading provider of premium material handling, construction and environmental processing equipment and related services, today announced that its Board of Directors approved the quarterly dividend on its Series A Cumulative Perpetual Preferred Stock in the amount of $625 per preferred share. This will equate to a dividend of $0.625 for each of the outstanding Depositary Shares representing a 1/1000th fractional interest in one share of Series A Preferred. The dividend payment date is October 30, 2026, to shareholders of record at the close of business on October 15, 2026.

About Alta Equipment Group Inc.
Alta owns and operates one of the largest integrated equipment dealership platforms in North America. Through its branch network, the Company sells, rents, and provides parts and service support for several categories of specialized equipment, including lift trucks and other material handling equipment, heavy and compact earthmoving equipment, crushing and screening equipment, environmental processing equipment, cranes and aerial work platforms, concrete and asphalt paving equipment, other construction equipment and allied products. Alta has operated as an equipment dealership for 42 years and has over 80 total locations across Michigan, Illinois, Indiana, Ohio, Pennsylvania, Massachusetts, Maine, Connecticut, New Hampshire, Vermont, Rhode Island, New York, Virginia, Nevada and Florida, and the Canadian provinces of Ontario, New Brunswick, and Quebec. Alta offers its customers a one-stop shop for their equipment needs through its broad, industry-leading product portfolio. More information can be found at www.altg.com.

Contacts

Investors:
Kevin Inda
SCR Partners, LLC
kevin@scr-ir.com
(225) 772-0254

FREDERICK, Md., Oct. 02, 2026 (GLOBE NEWSWIRE) — Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to four new employees. On October 1, 2026, the Company issued to these employees options to purchase an aggregate of 121,900 shares of the Company’s common stock with an exercise price of $7.22, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on October 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on October 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com